Contineum Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	50	-	-
Gross Profit	-	50	-	-
Selling, General & Admin	13.66	7.26	6.63	6.29
Research & Development	37.24	26.67	16.09	22.36
Operating Expenses	50.89	33.92	22.72	28.65
Operating Income	-50.89	16.08	-22.72	-28.65
Interest Expense	-	-0.21	-0.39	-0.33
Interest & Investment Income	8.91	4.61	0.76	0.08
Other Non Operating Income (Expenses)	-0.27	2.7	-1.91	-0.1
Pretax Income	-42.26	23.17	-24.25	-29
Income Tax Expense	-	0.45	-	-
Net Income	-42.26	22.72	-24.25	-29
Preferred Dividends & Other Adjustments	-	19.57	-	-
Net Income to Common	-42.26	3.15	-24.25	-29
Shares Outstanding (Basic)	19	2	2	2
Shares Outstanding (Diluted)	19	3	2	2
Shares Change (YoY)	469.95%	51.38%	6.35%	-
EPS (Basic)	-2.18	1.36	-10.81	-13.75
EPS (Diluted)	-2.18	0.08	-10.81	-13.77
Free Cash Flow	-33.36	18.94	-20.24	-26.43
Free Cash Flow Per Share	-1.72	5.58	-9.02	-12.53
Gross Margin	-	100.00%	-	-
Operating Margin	-	32.15%	-	-
Profit Margin	-	6.29%	-	-
Free Cash Flow Margin	-	37.87%	-	-
EBITDA	-50.64	16.27	-22.39	-28.32
EBITDA Margin	-	32.54%	-	-
D&A For EBITDA	0.26	0.2	0.33	0.33
EBIT	-50.89	16.08	-22.72	-28.65
EBIT Margin	-	32.15%	-	-
Effective Tax Rate	-	1.94%	-	-

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q